MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

Home・Aandelen Lijst・Cronos Group Inc

Cronos Group Inc

Gesloten

SectorGezondheidszorg

2.51 3.72

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.43

Max

2.5300000000000002

Belangrijke statistieken
By Trading Economics
Inkomsten	-26M 2.4M
Verkoop	55M 91M
K/W Sectorgemiddelde	23.909 57.05
Winstmarge	2.67
Werknemers	610
EBITDA	-75M -45M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+14.8% upside

Dividenden
By Dow Jones
Volgende Winsten	7 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-72M 938M
Vorige openingsprijs	-1.21
Vorige sluitingsprijs	2.51

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

1.84 / N/A Steun & Weerstand

Cronos Group Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

31 mrt 2026, 23:31 UTC

Populaire aandelen

Stocks to Watch: Nike, RH, NCino

31 mrt 2026, 22:35 UTC

Winsten

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 apr 2026, 00:00 UTC

Acquisities, Fusies, Overnames

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 mrt 2026, 23:50 UTC

Acquisities, Fusies, Overnames

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 mrt 2026, 23:43 UTC

Marktinformatie

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 mrt 2026, 23:33 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 mrt 2026, 23:21 UTC

Winsten

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 mrt 2026, 23:14 UTC

Marktinformatie

Winsten

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 mrt 2026, 23:12 UTC

Marktinformatie

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 mrt 2026, 22:36 UTC

Winsten

China Vanke 2025 Loss Widens >000002.SZ

31 mrt 2026, 22:36 UTC

Winsten

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 mrt 2026, 22:36 UTC

Winsten

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 mrt 2026, 22:36 UTC

Winsten

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 mrt 2026, 22:36 UTC

Winsten

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 mrt 2026, 21:46 UTC

Acquisities, Fusies, Overnames

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 mrt 2026, 21:36 UTC

Marktinformatie

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 mrt 2026, 21:35 UTC

Winsten

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 mrt 2026, 21:35 UTC

Winsten

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 mrt 2026, 21:35 UTC

Winsten

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 mrt 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 mrt 2026, 21:33 UTC

Winsten

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 mrt 2026, 21:32 UTC

Winsten

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 mrt 2026, 21:28 UTC

Winsten

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 mrt 2026, 21:26 UTC

Winsten

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 mrt 2026, 21:25 UTC

Winsten

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 mrt 2026, 21:24 UTC

Marktinformatie

Winsten

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 mrt 2026, 21:22 UTC

Winsten

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 mrt 2026, 21:22 UTC

Winsten

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 mrt 2026, 21:21 UTC

Winsten

Nike's Digital Channel Still Too Promotional, CFO Says

31 mrt 2026, 21:20 UTC

Winsten

Nike CEO: Converse Remains Important to Portfolio

Peer Vergelijking

Prijswijziging

Cronos Group Inc Prognose

Koersdoel

By TipRanks

14.8% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 2.87 USD 14.8%

Hoogste 3.24 USD

Laagste 2.3 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Cronos Group Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

3 ratings

Buy

Hold

Sell

Gebaseerd op 3 analisten die aandelenratings hebben gegeven aan Cronos Group Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

1.84 / N/ASteun & Weerstand

Recent bullish events outweigh bearish events.

There are no events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Cronos Group Inc

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.